Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$72.79
+0.2%
$69.42
$60.56
$82.49
$8.85B0.861.72 million shs1.23 million shs
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$31.33
$31.33
$19.45
$31.79
$2.77B0.731.26 million shsN/A
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€25.31
+2.9%
€22.90
€16.85
€25.75
$7.66B0.53338,750 shs358,600 shs
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$95.11
-2.2%
$76.98
$14.14
$99.01
$8.28B0.211.31 million shs968,274 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Henry Schein, Inc. stock logo
HSIC
Henry Schein
+1.10%+3.59%+1.44%+4.20%+8.04%
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
0.00%0.00%0.00%+0.29%+27.83%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
+4.61%+2.66%+11.11%+17.67%+45.95%
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
+0.18%+4.62%+29.52%+51.48%+519.63%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Henry Schein, Inc. stock logo
HSIC
Henry Schein
2.8161 of 5 stars
1.31.00.03.42.21.71.9
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
1.7372 of 5 stars
1.00.02.51.71.31.72.5
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
1.8436 of 5 stars
0.04.00.80.02.40.01.9
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
2.4114 of 5 stars
2.53.00.00.03.42.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Henry Schein, Inc. stock logo
HSIC
Henry Schein
2.64
Moderate Buy$79.308.94% Upside
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
2.09
Hold$26.57-15.19% Downside
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
2.86
Moderate BuyN/AN/A
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
3.00
Buy$101.106.30% Upside

Current Analyst Ratings Breakdown

Latest HSIC, PDCO, STVN, and VRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$76.00 ➝ $160.00
6/20/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$107.00 ➝ $138.00
6/18/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$92.00 ➝ $116.00
6/11/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$90.00 ➝ $100.00
6/11/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$95.00 ➝ $110.00
6/2/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$85.00 ➝ $90.00
5/6/2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$80.00 ➝ $75.00
5/6/2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$90.00 ➝ $86.00
4/30/2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$83.00 ➝ $77.00
4/30/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$93.00 ➝ $107.00
4/30/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$75.00 ➝ $85.00
(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$12.67B0.70$7.35 per share9.91$32.33 per share2.25
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$6.51B0.43$3.42 per share9.17$11.18 per share2.80
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
$1.19B6.42€0.78 per share32.58€5.02 per share5.04
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$42.28M191.50N/AN/A$2.56 per share37.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$390M$3.2022.7514.502.343.21%14.87%5.82%8/5/2025 (Estimated)
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$185.93M$1.5418.3212.842.712.37%19.77%6.66%8/26/2025 (Estimated)
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
$127.45M€0.5149.6343.642.3511.14%10.00%6.03%N/A
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-$173.42M-$2.00N/A3,170.33N/AN/A-69.65%-28.00%8/6/2025 (Estimated)

Latest HSIC, PDCO, STVN, and VRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2025Q1 2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$1.11$1.15+$0.04$0.88$3.24 billion$3.17 billion
4/29/2025Q1 2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Henry Schein, Inc. stock logo
HSIC
Henry Schein
N/AN/AN/AN/AN/A
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$1.043.32%N/A67.53%N/A
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/AN/AN/AN/A1 Years
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
N/AN/AN/AN/AN/A

Latest HSIC, PDCO, STVN, and VRNA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/2/2025
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
annual€0.060.3%6/5/20256/5/20257/17/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Henry Schein, Inc. stock logo
HSIC
Henry Schein
0.50
1.38
0.75
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
0.34
1.37
0.76
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.22
1.83
1.26
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
1.07
8.86
8.73
CompanyEmployeesShares OutstandingFree FloatOptionable
Henry Schein, Inc. stock logo
HSIC
Henry Schein
25,000121.72 million120.41 millionOptionable
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
7,70088.47 million86.64 millionOptionable
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
5,521302.84 million300.72 millionOptionable
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
3085.13 million81.05 millionOptionable

Recent News About These Companies

Verona Pharma: An Impressive Initial Launch
Verona Pharma plc (NASDAQ:VRNA) CFO Sells $4,560,000.00 in Stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

Henry Schein stock logo

Henry Schein NASDAQ:HSIC

$72.79 +0.11 (+0.15%)
Closing price 04:00 PM Eastern
Extended Trading
$72.79 0.00 (0.00%)
As of 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Henry Schein, Inc. provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products, such as branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners; and value-added practice solutions comprising practice consultancy, education, revenue cycle management and financial services, e-services, practice technology, and network and hardware services, as well as consulting, and continuing education services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

Patterson Companies stock logo

Patterson Companies NASDAQ:PDCO

$31.33 0.00 (0.00%)
As of 04/17/2025

Patterson Companies, Inc. engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada. The company operates through three segments: Dental, Animal Health, and Corporate segments. The Dental segment offers consumable products, including infection control, restorative materials, and instruments; basic and advanced technology and dental equipment; practice optimization solutions, such as practice management software, e-commerce, revenue cycle management, patient engagement solutions, and clinical and patient education systems. It also provides a range of related services comprising software and design services, maintenance and repair, and equipment financing. The Animal Health segment distributes biologicals, pharmaceuticals, vaccines, parasiticides, diagnostics, prescription and non-prescription diets, nutritional's, consumable supplies, equipment, and software, as well as value-added services. This segment also provides private label portfolio of products to veterinarians, producers, and retailers under the Aspen, First Companion, and Patterson Veterinary brands. The Corporate segment offers customer financing services; and sells other miscellaneous products. It serves dentists, laboratories, institutions, other healthcare professionals, veterinarians, other animal health professionals, production animal operators, and animal health product retailers. The company was formerly known as Patterson Dental Company and changed its name to Patterson Companies, Inc. in June 2004. Patterson Companies, Inc. was founded in 1877 and is headquartered in Saint Paul, Minnesota.

Stevanato Group stock logo

Stevanato Group NYSE:STVN

€25.31 +0.72 (+2.93%)
As of 03:59 PM Eastern

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

Verona Pharma PLC American Depositary Share stock logo

Verona Pharma PLC American Depositary Share NASDAQ:VRNA

$95.11 -2.11 (-2.17%)
Closing price 04:00 PM Eastern
Extended Trading
$95.58 +0.47 (+0.49%)
As of 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.